1. Home
  2. SUPN vs ADUS Comparison

SUPN vs ADUS Comparison

Compare SUPN & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • ADUS
  • Stock Information
  • Founded
  • SUPN 2005
  • ADUS 1979
  • Country
  • SUPN United States
  • ADUS United States
  • Employees
  • SUPN N/A
  • ADUS N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • ADUS Medical/Nursing Services
  • Sector
  • SUPN Health Care
  • ADUS Health Care
  • Exchange
  • SUPN Nasdaq
  • ADUS Nasdaq
  • Market Cap
  • SUPN 1.7B
  • ADUS 1.8B
  • IPO Year
  • SUPN 2012
  • ADUS 2009
  • Fundamental
  • Price
  • SUPN $31.70
  • ADUS $110.91
  • Analyst Decision
  • SUPN Hold
  • ADUS Buy
  • Analyst Count
  • SUPN 2
  • ADUS 10
  • Target Price
  • SUPN $36.00
  • ADUS $143.50
  • AVG Volume (30 Days)
  • SUPN 420.5K
  • ADUS 182.8K
  • Earning Date
  • SUPN 05-06-2025
  • ADUS 05-05-2025
  • Dividend Yield
  • SUPN N/A
  • ADUS N/A
  • EPS Growth
  • SUPN N/A
  • ADUS 9.84
  • EPS
  • SUPN 1.11
  • ADUS 4.42
  • Revenue
  • SUPN $667,997,000.00
  • ADUS $1,211,561,000.00
  • Revenue This Year
  • SUPN N/A
  • ADUS $24.03
  • Revenue Next Year
  • SUPN $9.14
  • ADUS $5.80
  • P/E Ratio
  • SUPN $28.49
  • ADUS $25.39
  • Revenue Growth
  • SUPN 11.82
  • ADUS 11.38
  • 52 Week Low
  • SUPN $25.53
  • ADUS $88.96
  • 52 Week High
  • SUPN $40.28
  • ADUS $136.72
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 47.88
  • ADUS 68.13
  • Support Level
  • SUPN $29.16
  • ADUS $103.15
  • Resistance Level
  • SUPN $33.28
  • ADUS $112.53
  • Average True Range (ATR)
  • SUPN 1.19
  • ADUS 3.09
  • MACD
  • SUPN 0.02
  • ADUS 1.10
  • Stochastic Oscillator
  • SUPN 61.65
  • ADUS 89.66

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Share on Social Networks: